COVID-19 Pilot Funding Program
Illustration of a COVID-19 particle

By leveraging our existing pilot program infrastructure and collaborating with the UK CURE Alliance, we rapidly launched a pilot funding program for research projects in three areas. Applications are accepted on a rolling basis. Full-time faculty in all title series at the University of Kentucky are eligible to apply. 

Please note that as of July 7, 2020, we are not accepting new applications due to commitments to already-funded projects .

Questions can be directed to Joel Thompson, PhD, CCTS Research Development Director, at joel.thompson@uky.edu. 

 


Core 1: Health and Biomedical Science 
 


Core 2: Materials and Methods 
 



Core 3: Social Sciences 
 



Funding Priorities

Emphasis is on applications that have an impact on the evolving COVID-19 pandemic in the following areas:

  • Basic science approaches on SARS-CoV-2 and its receptor, animal models of COVID-19, risk factors and their direct association with COVID-19
  • Clinical research involving the diagnosis, treatment, prevention and a better understanding of the epidemiology of COVID-19 
  • Community impact of COVID-19. It is likely that these studies will promote team science and involve in the investigating team a professional with knowledge of the pandemic and/or its causative agent SARS-CoV-2 (e.g. clinician, epidemiologist, etc) 
  • High impact on expanding knowledge or developing new knowledge on the COVID-19 pandemic and SARS-CoV-2.

It is an expectation that these funds will be used to obtain preliminary data for an extramural grant submission related to COVID-19/SARS-CoV-2.

Proposals are reviewed on an ongoing basis by members of the UK CURE COVID-19 Review Committee and funding decisions are made based on scientific merit, relevance to program goals, and potential for extramural support.

 

 

 

COVID-19 News from the CCTS

  • LEX18 Covid-19 Blood Clot Story
    • Oct 16 2020

    The research, supported by a COVID-19 pilot grant from the CCTS, suggests lung damage caused by COVID-19 might be to blame for prolonged clot risk.

  • Behind the Blue logo
    • Oct 13 2020

    Dr. Lisa Cassis, UK’s vice president for research, oversees the university’s vast medical and nonmedical research efforts. On this episode of "Behind the Blue," she discusses the many areas UK's Office of Research is prioritizing, including greater diversity and inclusion, the increasing commitment to opportunities for undergraduate research, returning research efforts to higher capacity during the COVID-19 pandemic, and more.

  • UK researcher Jeremy Wood, pictured in his lab wearing a white coat, is co-leading research that may provide answers for why so many COVID-19 patients experience blood clotting.
    • Sep 17 2020

    The study suggests that localized inflammation in the lungs caused by COVID-19 may be responsible for the increased presence of blood clots in patients, and that the risk of thrombosis could persist after the infection clears.